XNASBGLC
Market cap4mUSD
Dec 20, Last price
0.23USD
1D
-12.80%
1Q
-43.31%
IPO
-44.17%
Name
BioNexus Gene Lab Corp
Chart & Performance
P/E
—
P/S
0.42
EPS
—
Div Yield, %
1.49%
Shrs. gr., 5y
23.49%
Rev. gr., 5y
115.07%
Revenues
10m
-10.60%
Net income
-3m
L+638.57%
CFO
-1m
L
Profile
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 9,771 -10.60% | 10,929 -18.21% | 13,363 17.31% | |||||
Cost of revenue | 12,850 | 11,399 | 12,373 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (3,080) | (470) | 989 | |||||
NOPBT Margin | 7.40% | |||||||
Operating Taxes | 22 | 52 | 291 | |||||
Tax Rate | 29.44% | |||||||
NOPAT | (3,101) | (523) | 698 | |||||
Net income | (2,629) 638.57% | (356) -147.36% | 752 -31.31% | |||||
Dividends | (115) | (22) | ||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 5,750 | 150 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 35 | 17 | 40 | |||||
Long-term debt | 232 | 97 | 114 | |||||
Deferred revenue | (31) | (28) | ||||||
Other long-term liabilities | 31 | 28 | ||||||
Net debt | (7,362) | (3,156) | (2,719) | |||||
| Cash flow | ||||||||
Cash from operating activities | (1,302) | 544 | 9 | |||||
CAPEX | (149) | (54) | (3) | |||||
Cash from investing activities | (383) | (450) | (491) | |||||
Cash from financing activities | 5,754 | 116 | (28) | |||||
FCF | (132) | (1,132) | 6,091 | |||||
| Balance | ||||||||
Cash | 5,929 | 2,119 | 2,124 | |||||
Long term investments | 1,700 | 1,151 | 749 | |||||
Excess cash | 7,141 | 2,723 | 2,205 | |||||
Stockholders' equity | 14,670 | 11,677 | 12,192 | |||||
Invested Capital | 2,651 | 3,998 | 4,954 | |||||
ROIC | 15.21% | |||||||
ROCE | 13.76% | |||||||
| EV | ||||||||
Common stock shares outstanding | 15,875 | 14,410 | 14,268 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (2,971) | (365) | 1,098 | |||||
EV/EBITDA | ||||||||
Interest | 14 | 12 | 13 | |||||
Interest/NOPBT | 1.31% | |||||||